Hear Adaptive Biotechnologies' June 3 investor talk live online
Adaptive Biotechnologies (NASDAQ: ADPT) announced its participation in two upcoming investor conferences. The company will host 1x1 meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28 and present at the William Blair 46th Annual Growth Stock Conference on June 3 at 3:20 p.m. Central Time. A live and archived webcast of the William Blair presentation will be available on the Investors section of the company's website.
Adaptive Biotechnologies (ADPT) CFO tax-related share sale leaves 256,725 shares held
Adaptive Biotechnologies CFO Kyle Piskel sold 3,115 shares of common stock at $13.04 per share on May 18, 2026, to cover tax withholding obligations from vesting restricted stock units (RSUs). This "sell to cover" transaction was mandated by the company's equity incentive plan and was not a discretionary trade. After the sale, Piskel directly holds 256,725 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies CFO Kyle Piskel sells $40,619 in stock
Adaptive Biotechnologies CFO Kyle Piskel sold 3,115 shares of company stock for $40,619 on May 18, 2026. This transaction was a "sell to cover" to meet tax withholding obligations for restricted stock units and not a discretionary trade. Following the sale, Piskel directly holds 256,725 shares, and the company recently reported strong Q1 2026 revenue of $70.9 million, exceeding expectations.
UBS Group AG Purchases 257,947 Shares of Adaptive Biotechnologies Corporation $ADPT
UBS Group AG significantly increased its stake in Adaptive Biotechnologies Corporation, purchasing an additional 257,947 shares in the fourth quarter. This acquisition brings their total holding to 511,927 shares, valued at approximately $8.3 million. Despite positive analyst sentiment and strong quarterly earnings, recent insider selling by the CEO and other executives has been noted.
Adaptive Biotechnologies (Nasdaq:ADPT) - Stock Analysis
Adaptive Biotechnologies (ADPT) is valued 36.9% below Simply Wall St's fair value estimate, despite being currently unprofitable. The company's Minimal Residual Disease (MRD) segment, particularly its clonoSEQ test, is driving significant revenue growth and is central to its path toward profitability, offsetting declines in Immune Medicine revenue. Recent updates include raised revenue guidance for 2026, narrowing losses, and analyst consensus anticipating the company to break even by 2028.
Viking firms hold 18.8% of Adaptive Biotechnologies (NASDAQ: ADPT)
Viking Global entities have filed an amended Schedule 13G/A, disclosing that various Viking firms collectively hold 18.8% of Adaptive Biotechnologies (NASDAQ: ADPT), amounting to 29,993,708 shares of Common Stock as of March 31, 2026. The amendment also formalizes the removal of David C. Ott as a reporting person following his retirement, without indicating any change in share counts or transactions. This filing serves as an update to ownership details, reflecting internal personnel changes rather than a shift in economic ownership.
Proposed sale of 3,160 RSUs by ADPT (NASDAQ: ADPT) reported
Morgan Stanley Smith Barney LLC has filed a Form 144 notice reporting a proposed sale of 3,160 Restricted Stock Units (RSUs) of Adaptive Biotechnologies Corp (ADPT) with an effective date of May 15, 2026. This filing is a regulatory notice of intent to sell, not a completed transaction. The document also noted a prior sale by Kyle Piskel of 18,672 shares on March 11, 2026, for $245,863.56.
ADPT SEC Filings - Adaptive Biotechnologies 10-K, 10-Q, 8-K Forms
This article provides a compilation of recent SEC filings for Adaptive Biotechnologies (ADPT), including Form 144, and several Form 4 filings detailing insider stock transactions. It highlights share sales to cover RSU taxes, director stock grants, and awards to various officers such as the Chief People Officer, Chief Commercial Officers, President and COO, Chief Scientific Officer, and Chief Financial Officer. Each filing entry includes a summary, AI-generated impact, and sentiment analysis by Rhea-AI.
ADPT SEC Filings - Adaptive Biotechnologies 10-K, 10-Q, 8-K Forms
This article provides access to Adaptive Biotechnologies Corporation's (ADPT) SEC filings, including 8-K, 10-K, and 10-Q reports, which detail financial results, material agreements, and corporate events. It highlights recent insider transactions, such as stock grants to directors and the CEO, as well as sales by the CEO, COO, and CSO, often executed under Rule 10b5-1 trading plans. StockTitan offers AI-powered summaries and sentiment analysis for these filings to help investors analyze ADPT's financial condition and strategic direction.
ADPT SEC Filings - Adaptive Biotechnologies 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Adaptive Biotechnologies (ADPT) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside insider trading reports. Stock Titan offers AI-powered summaries and impact analysis for each filing, helping users quickly understand material events and financial disclosures related to the company's Minimal Residual Disease (MRD) and Immune Medicine businesses. Recent filings include details on insider stock sales, RSU registrations, and amendments to passive investment disclosures.
ADPT SEC Filings - Adaptive Biotechnologies 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Adaptive Biotechnologies (ADPT) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It highlights key corporate events, financial results, and strategic agreements, with AI-powered summaries for each filing. Recent insider trading activities, primarily "sell to cover" transactions for tax withholding, are also detailed.
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.
Adaptive Biotechnologies' COO, Julie Rubinstein, sold 19,037 shares for approximately $271,000 as part of a pre-planned trading strategy. This sale represented a modest 4.8% of her direct holdings, indicating she maintains a substantial economic interest in the company. Investors should view this not as a red flag, but as a routine transaction, especially considering the company's strong sales growth and reduced operating losses in 2025.
ADPT SEC Filings - Adaptive Biotechnologies 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Adaptive Biotechnologies (ADPT) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights recent filings detailing insider stock sales by Harlan Robins and Chad M. Robins, BlackRock's 7.9% stake, and stock transactions by CPO Francis Lo and CFO Kyle Piskel. The platform offers AI-powered summaries and impact analysis for investors seeking regulatory disclosures.
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast
Adaptive Biotechnologies exceeded Q1 2026 revenue forecasts, reporting $70.9 million, primarily driven by a 53% year-over-year increase in its Minimal Residual Disease (MRD) business. The strong performance led to a 1.38% rise in stock price during after-hours trading and prompted the company to raise its full-year MRD revenue guidance. The company emphasized strong financial discipline and expanding gross margins, while also noting continued investment in growth areas like EMR integrations and data generation.
How Strong MRD Growth and Upgraded 2026 Guidance Will Impact Adaptive Biotechnologies (ADPT) Investors
Adaptive Biotechnologies (ADPT) reported a strong first quarter in 2026, with revenue up and a narrower net loss, driven by significant growth in its Minimal Residual Disease (MRD) testing segment. Management subsequently raised its full-year 2026 MRD revenue guidance to US$260–US$270 million, which is crucial for offsetting the impact of the Genentech collaboration termination and supporting the company's path to profitability. This report examines how this positive MRD performance and updated guidance influence the investment outlook for ADPT, highlighting both opportunities and ongoing risks related to profitability.
ADPT SEC Filings - Adaptive Biotechnologies 10-K, 10-Q, 8-K Forms
This page provides access to Adaptive Biotechnologies (ADPT) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside Form 4 insider trading disclosures. It offers AI-powered summaries of these regulatory documents, impact scoring, and sentiment analysis for investors. Recent filings highlight insider stock sales by the CEO, CPO, and other executives, as well as the company's Q3 2025 financial results, which showed increased revenue and net income, partly due to the termination of a collaboration agreement with Genentech.
Adaptive Biotechnologies earnings on deck after 55% revenue surge By Investing.com
Adaptive Biotechnologies is expected to report its Q1 2026 earnings, with analysts forecasting a loss of 16 cents per share on revenue of $60.9 million. While this indicates sequential revenue decline from Q4 2025, it represents year-over-year improvement in losses and revenue growth. Investors will be closely watching the trajectory of the company's minimal residual disease (MRD) business and its path to profitability.
Q1 2026 Adaptive Biotechnologies Corp Earnings Call Transcript
This article provides the Q1 2026 earnings call transcript for Adaptive Biotechnologies Corp (NAS:ADPT). It includes details about the company's financial results presented by Karina Calzadilla, Head of Investor Relations. The transcript outlines the initial remarks and financial disclosures made during the conference call.
Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call
Adaptive Biotechnologies reported strong Q1 2026 results, with MRD revenue up 53% year-over-year, driven by clinical and pharma segments. The company raised its full-year MRD revenue guidance to $260-$270 million, anticipating at least 35% growth in clinical volumes, and achieved significant gross margin expansion for sequencing. Adaptive Biotechnologies also highlighted the success of its Clonaseq test, a growing pharma backlog, and advancements in its immune medicine programs.
Earnings call transcript: Adaptive Biotechnologies Q1 2026 revenue beats forecast
Adaptive Biotechnologies (ADPT) reported Q1 2026 revenue of $70.9 million, significantly exceeding forecasts and marking a 45% year-over-year increase, driven largely by its Minimal Residual Disease (MRD) business. The company raised its full-year 2026 MRD revenue guidance to $260 million-$270 million and expects clinical volume growth of at least 35%. Despite a net loss for the quarter, the strong performance in the MRD segment and optimistic market reaction led to a 1.38% increase in stock price during after-hours trading.
Adaptive Biotechnologies Corp reports results for the quarter ended March 31 - Earnings Summary
Adaptive Biotechnologies Corp announced its financial results for the quarter that ended on March 31. The report contains an earnings summary for the specified period. This brief article from Reuters provides a summary of the company's performance.
Adaptive Biotechnologies: Q1 Earnings Snapshot
Adaptive Biotechnologies Corp. (ADPT) reported a first-quarter loss of $20 million, or 13 cents per share, which beat Wall Street's expectations. The company also exceeded revenue forecasts, posting $70.9 million, compared to an expected $61.8 million. Despite these positive results, the company's shares have dropped 15% since the beginning of the year, though they rose 38% in the last 12 months.
Adaptive Biotechnologies (NASDAQ: ADPT) lifts 2026 MRD outlook after 35% Q1 revenue growth
Adaptive Biotechnologies reported strong Q1 2026 results, with total revenue increasing 35% to $70.9 million, primarily driven by a 53% surge in its Minimal Residual Disease (MRD) business. The company also narrowed its net loss and improved Adjusted EBITDA, leading to a raised full-year 2026 MRD revenue guidance to $260–$270 million, signifying continued confidence in its core growth segment. The Immune Medicine segment, however, saw a 57% decline in revenue due to lower Genentech-related activity.
Adaptive lifts 2026 MRD outlook after $70.9M quarter, 41% test gain
Adaptive Biotechnologies reported strong Q1 2026 results, with total revenue reaching $70.9 million, driven primarily by Minimal Residual Disease (MRD) revenue which surged 53% year-over-year to $67.1 million. The company also saw a 41% increase in clonoSEQ test volume and subsequently raised its full-year 2026 MRD revenue guidance to between $260 million and $270 million. Despite a net loss of $20.0 million, Adaptive improved its Adjusted EBITDA loss and maintained a healthy cash position.
Adaptive Biotechnologies: Q1 Earnings Snapshot
Adaptive Biotechnologies Corp. (ADPT) reported a first-quarter loss of $20 million, or 13 cents per share, which was better than Wall Street's expectations of a 16-cent loss per share. The company also exceeded revenue forecasts, posting $70.9 million against an expected $61.8 million. Despite a 15% drop in shares since the beginning of the year, the stock has risen 38% in the last 12 months.
Adaptive Biotechnologies earnings on deck after 55% revenue surge
Adaptive Biotechnologies (NASDAQ: ADPT) is scheduled to release its first-quarter earnings after market close on Tuesday. Analysts anticipate a sequential decline in revenue and a wider loss compared to the previous quarter, despite year-over-year improvements in narrowing losses and revenue growth. Wall Street maintains a bullish outlook on the stock, with 7 out of 8 analysts recommending a "buy" and a consensus price target indicating significant upside.
Adaptive Biotechnologies Corp (HAM:1HM) Stock News, Headlines & Updates
This article provides news and updates for Adaptive Biotechnologies Corp (HAM:1HM), highlighting recent insider selling activities by Harlan Robins and Chad Robins in April 2026. It also mentions the upcoming first-quarter 2026 financial results report scheduled for May 5, 2026, and provides current stock metrics like P/E, P/B, and market capitalization.
Adaptive Biotechnologies Corp (HAM:1HM) - Valuation Measures & Financial Statistics
This GuruFocus article provides a comprehensive overview of Adaptive Biotechnologies Corp (HAM:1HM), detailing its current valuation measures and financial statistics. It lists numerous fundamental, valuation ratio, profitability, price, dividend, income statement, balance sheet, and cash flow statement categories available for analysis. The article also highlights that GuruFocus has detected two severe warning signs for 1HM.
Adaptive Biotechnologies Corp (HAM:1HM) Stock Price, Trades & News
This article provides a detailed overview of Adaptive Biotechnologies Corp (HAM:1HM) stock, covering its current price, market capitalization, financial strength, growth, momentum, liquidity, and profitability ranks. It also highlights upcoming earnings dates and recent news related to the company, indicating two severe warning signs detected by GuruFocus.
Adaptive Biotechnologies (ADPT) exec trades shares under Rule 10b5-1 plan
Julie Rubinstein, President and COO of Adaptive Biotechnologies (ADPT), reported an option exercise and corresponding share sale under a pre-arranged Rule 10b5-1 trading plan. On April 27, 2026, she sold 19,037 shares of common stock at a weighted average price of $14.23 per share and exercised options for 14,707 shares at $8.46 per share. These transactions were detailed in an SEC Form 4 filing.
Adaptive Biotechnologies COO Julie Rubinstein sells $270k in stock
Adaptive Biotechnologies COO Julie Rubinstein sold 19,037 shares of the company's stock for $270,896 and simultaneously acquired 14,707 shares through option exercises for $124,421. The sales, executed under a 10b5-1 plan, occurred when the stock was valued at $14.23 per share, higher than the current trading price of $13.53, though the stock has seen a significant 77.86% return over the past year. Analysts have recently raised price targets for Adaptive Biotechnologies following a strong Q4 2025 earnings report.
[ARS] Adaptive Biotechnologies Corp SEC Filing
Adaptive Biotechnologies Corp (ADPT) filed an ARS form with the SEC on April 24, 2026, at 4:32 PM. The filing's impact and sentiment are noted as "Low" and "Neutral," respectively. This document, available as a PDF, is accessible through the SEC EDGAR database.
Adaptive Biotechnologies (ADPT) president sells 57K shares, exercises options
Adaptive Biotechnologies Corp's President and COO, Julie Rubinstein, reported exercising stock options for 44,166 shares at $8.46 and selling 57,180 shares in open-market transactions at average prices around $14 between April 22-24, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 382,132 shares of Common Stock and 60,438 stock options.
Adaptive Biotechnologies COO Julie Rubinstein sells $798k in stock
Julie Rubinstein, COO of Adaptive Biotechnologies Corp, sold approximately $798,423 worth of company stock over three days in late April under a pre-arranged Rule 10b5-1 trading plan. Concurrently, she acquired shares by exercising stock options totaling about $373,644. These transactions left her with 382,132 shares and 60,438 unexercised options, following a period where the stock returned 79%, and the company performed strongly in Q4 2025, exceeding analyst expectations.
Adaptive Biotechnologies COO Julie Rubinstein sells $798k in stock By Investing.com
Adaptive Biotechnologies COO Julie Rubinstein sold approximately $798,423 worth of company stock over three days in late April, executed under a pre-arranged trading plan. Concurrently, she acquired 44,166 shares by exercising stock options totaling about $373,644. These transactions occurred after a significant 79% stock return, though InvestingPro analysis suggests the shares are currently overvalued.
Adaptive Biotechnologies COO Julie Rubinstein sells $798k in stock By Investing.com
Adaptive Biotechnologies COO Julie Rubinstein sold approximately $798,423 worth of the company's common stock in late April 2026, executing these sales under a pre-arranged Rule 10b5-1 trading plan. Despite the stock's 79% return over the past year, InvestingPro analysis suggests it is currently trading above its Fair Value. Concurrently, Rubinstein exercised stock options to acquire shares worth about $373,644, maintaining a significant direct holding in the company.
How many employees work at Adaptive Biotechnologies?
Adaptive Biotechnologies Corp. currently has 707 employees, as measured by Revelio Labs' workforce intelligence data updated in December 2025. This represents a 0.1% year-over-year growth rate. The article also provides historical employee headcount data and other workforce metrics like average salary, tenure, and active job postings.
Adaptive Biotechnologies COO Julie Rubinstein sells $1.01m in stock
Adaptive Biotechnologies COO Julie Rubinstein sold $1.01 million worth of common stock and acquired $517,879 worth of stock through option exercises between April 17 and April 21, 2026. These transactions were executed under a Rule 10b5-1 trading plan. The shares of Adaptive Biotechnologies (ADPT) have shown significant volatility, with a 108% return over the past year but a 12.5% pullback year-to-date from its 52-week high.
Adaptive Biotechnologies COO Julie Rubinstein sells $1.01m in stock
Adaptive Biotechnologies COO Julie Rubinstein sold $1.01 million worth of stock and acquired $517,879 worth of stock between April 17 and April 21, 2026, under a Rule 10b5-1 trading plan. The transactions occurred while ADPT shares showed volatility, with sales at weighted average prices between $14.55 and $14.66 and acquisitions through stock options ranging from $8.46 to $12.14. Analysts maintain a bullish outlook on Adaptive Biotechnologies, with price targets suggesting a potential upside of 44%, following strong Q4 2025 earnings.
Adaptive Biotechnologies (ADPT) COO sells shares, exercises options under 10b5-1 plan
Adaptive Biotechnologies President and COO Julie Rubinstein executed a series of pre-planned stock transactions under a Rule 10b5-1 trading plan. She exercised stock options for 56,047 shares and subsequently sold 69,061 shares in open-market transactions, averaging in the mid-$14 range. Following these transactions, Rubinstein maintains a substantial direct ownership position in the company's common stock.
Julie Rubinstein Sells 57,180 Shares of Adaptive Biotechnologies
Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of common stock for approximately $758,000, reducing her direct holdings by 19.4% since mid-March 2026. This transaction was executed under a pre-arranged 10b5-1 plan, suggesting it does not reflect her current sentiment toward the stock. Despite the sale, Rubinstein retains a significant economic interest through remaining shares and unexercised options, and investors are advised to focus on the company's growth in clonoSEQ volumes and biopharma collaboration revenues.
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means
Adaptive Biotechnologies' President and COO, Julie Rubinstein, has been executing a systematic sell program for her shares, disposing of 57,180 shares across multiple transactions in April 2026. This activity is part of a pre-committed 10b5-1 plan established in November 2026, meaning the sales do not reflect her immediate view of the stock but rather a scheduled liquidation. Despite these sales, Rubinstein retains a significant equity stake in the company.
Adaptive Biotechnologies Hits Day Low of $13.37 Amid Price Pressure
Adaptive Biotechnologies Corp. experienced a 9.7% drop in its stock value, hitting an intraday low of $13.37, contrasting with the S&P 500's gain. Despite this short-term decline and year-to-date downturn, the company boasts a 59.9% increase over the past year and consistent net sales growth. Adaptive Biotechnologies, operating in the Pharmaceuticals & Biotechnology sector with a market capitalization of $2,051 million, also shows strong institutional backing with 100% holdings.
Adaptive Biotechnologies president Rubinstein sells $826k in ADPT stock
Adaptive Biotechnologies President and COO Julie Rubinstein sold 57,180 shares of ADPT stock for approximately $826,251 between April 14 and April 16, 2026, while also exercising options to acquire 44,166 shares. The company's stock has seen an 88% return over the past year, though an InvestingPro analysis suggests it may be overvalued. The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan.
Adaptive Biotechnologies (ADPT) COO exercises options and sells 57,180 shares
Adaptive Biotechnologies' President and COO, Julie Rubinstein, exercised stock options for 44,166 shares at $8.46 per share and subsequently sold 57,180 shares in open-market transactions between April 14-16, 2026. These transactions, conducted under a Rule 10b5-1 trading plan, resulted in sales at weighted average prices between $14.18 and $14.61 per share. Following these activities, Rubinstein directly holds 408,160 shares of ADPT common stock.
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
Adaptive Biotechnologies (Nasdaq: ADPT) announced it will release its first-quarter 2026 financial results after market close on Tuesday, May 5, 2026. The company will also host a corresponding conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, accessible via its investor relations website. Adaptive Biotechnologies is a commercial-stage biotechnology company focused on diagnosing and treating diseases by translating the genetics of the adaptive immune system.
Adaptive Biotechnologies getting closer to key technical measure
This article indicates that Adaptive Biotechnologies is nearing a significant technical milestone. No further details are provided in the current content.
Adaptive Biotechnologies schedules May 5 webcast for Q1 2026 results
Adaptive Biotechnologies (Nasdaq: ADPT) announced it will report its first-quarter 2026 financial results after market close on Tuesday, May 5, 2026. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET, with a replay available within 24 hours. Investors can access the webcast on the company's Investors website.
Adaptive Biotechnologies (ADPT) moves 5.8% higher: Will this strength last?
This article reports that Adaptive Biotechnologies (ADPT) stock experienced a 5.8% increase, outperforming the market on a given day. The analysis suggests that while the stock saw a significant gain, investors should look at underlying growth prospects and recent analyst estimate revisions for a clearer picture of whether this upward trend can be sustained. The article aims to provide context for interpreting the stock's recent price movement.
Adaptive Biotechnologies (NASDAQ: ADPT) COO sells shares under 10b5-1 plan
Adaptive Biotechnologies Corp's President and COO, Julie Rubinstein, exercised stock options for 44,166 shares and subsequently sold 57,180 shares of common stock through open-market transactions. These transactions, executed on April 9, 10, and 13, were conducted under a pre-arranged Rule 10b5-1 trading plan established on November 18, 2025. Following these trades, Rubinstein directly holds 421,174 shares of ADPT common stock.
